NAS:AFMD (Germany) Also Trade In: Germany UK

Affimed NV $ 5.13 -0.47 (-8.39%)

Volume:
2,381,023
Avg Vol (1m):
1,831,613
Market Cap $:
594.60 Mil
Enterprise Value $:
482.75 Mil
PE Ratio:
0.00
PB Ratio:
8.05
Warning! GuruFocus has detected 4 Severe warning signs with AFMD. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for AFMD (Affimed NV) from 2014 to Mar 04 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Affimed NV stock (AFMD) PE ratio as of Mar 04 2021 is 0. More Details

Affimed NV PE Ratio (TTM) Chart

EMBED

Affimed NV PE Ratio (TTM) Historical Data

Total 1243
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Affimed NV PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-03-040.0 2020-12-290.0
2021-03-030.0 2020-12-280.0
2021-03-020.0 2020-12-240.0
2021-03-010.0 2020-12-230.0
2021-02-260.0 2020-12-220.0
2021-02-250.0 2020-12-210.0
2021-02-240.0 2020-12-180.0
2021-02-230.0 2020-12-170.0
2021-02-220.0 2020-12-160.0
2021-02-190.0 2020-12-150.0
2021-02-180.0 2020-12-140.0
2021-02-170.0 2020-12-110.0
2021-02-160.0 2020-12-100.0
2021-02-150.0 2020-12-090.0
2021-02-120.0 2020-12-080.0
2021-02-110.0 2020-12-070.0
2021-02-100.0 2020-12-040.0
2021-02-090.0 2020-12-030.0
2021-02-080.0 2020-12-020.0
2021-02-050.0 2020-12-010.0
2021-02-040.0 2020-11-300.0
2021-02-030.0 2020-11-270.0
2021-02-020.0 2020-11-250.0
2021-02-010.0 2020-11-240.0
2021-01-290.0 2020-11-230.0
2021-01-280.0 2020-11-200.0
2021-01-270.0 2020-11-190.0
2021-01-260.0 2020-11-180.0
2021-01-250.0 2020-11-170.0
2021-01-220.0 2020-11-160.0
2021-01-210.0 2020-11-130.0
2021-01-200.0 2020-11-120.0
2021-01-190.0 2020-11-110.0
2021-01-150.0 2020-11-100.0
2021-01-140.0 2020-11-090.0
2021-01-130.0 2020-11-060.0
2021-01-120.0 2020-11-050.0
2021-01-110.0 2020-11-040.0
2021-01-080.0 2020-11-030.0
2021-01-070.0 2020-11-020.0
2021-01-060.0 2020-10-300.0
2021-01-050.0 2020-10-290.0
2021-01-040.0 2020-10-280.0
2020-12-310.0 2020-10-270.0
2020-12-300.0 2020-10-260.0

Affimed NV PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325414 NAICS : 2836
Traded in other countries A28.Germany 0HL9.UK AFMD.USA
Address Im Neuenheimer Feld 582, Technologiepark, Heidelberg, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.